Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.39−0.05 (-1.13%)
Close on Nov 12, 2026Market cap $123.91MP/E –Yield –
Journey Medical statistics
80 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Q3 FY2026, expected soon
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 12, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 16.07
- 2.29
Enterprise valuationIndustry
- EV / Sales
- 1.83
- 2.60
Share statisticsIndustry
- Shares Change (YoY)
- 19.3%
- 10.9%
- Float
- 24M
- 49M
- Shares Held by Insiders
- 15.3%
- 12.1%
- Shares Held by Institutions
- 37.8%
- 56.4%
Short sellingIndustry
- Short Interest
- 3M
- –
- Short Interest Change
- 3.25%
- -0.76%
- Short % of Float
- 12.9%
- 9.04%
- Short % of Shares Outstanding
- 10.9%
- 6.30%
- Days to Cover
- 15.07
- 5.13
Stock price statisticsIndustry
- 52-Week High
- $9.55
- –
- 52-Week Low
- $4.25
- –
- 20-Day Moving Average
- $4.83
- –
- 50-Day Moving Average
- $5.96
- –
- 200-Day Moving Average
- $6.46
- –
- Average True Range (14)
- $0.32
- –
- Price Change (1 Week)
- 2.09%
- 1.51%
- Price Change (1 Month)
- -16.9%
- -2.35%
- Price Change (3 Months)
- -34.7%
- -21.1%
- Price Change (6 Months)
- -30.9%
- -22.6%
- Price Change (YTD)
- -43.1%
- -22.6%
- Price Change (1 Year)
- -51.5%
- -20.7%
- Price Change (3 Years)
- 10.6%
- -27.4%
- Price Change (5 Years)
- -53.8%
- -77.3%
- Price Change (10 Years)
- -87.5%
- -62.7%
- Average Volume (10 Days)
- 165,058
- –
- Average Volume (20 Days)
- 185,290
- –
- Average Volume (90 Days)
- 185,069
- –
- Relative Volume
- 1.00
- 0.79
- Relative Strength Index (14)
- 34.2
- 44.7
- Volatility (1 Year)
- 67.5%
- 80.4%
- Beta (5 Years)
- 0.68
- 1.07
MarginsIndustry
- Pretax Margin
- -7.32%
- -11.8%
- EBITDA Margin
- -2.89%
- -27.7%
Returns on capitalIndustry
- Return on Equity (ROE)
- -17.6%
- -51.2%
- Return on Assets (ROA)
- -5.40%
- -40.6%
- Return on Invested Capital (ROIC)
- -5.15%
- -32.9%
- Return on Capital Employed (ROCE)
- -3.99%
- -38.0%
Financial positionIndustry
- Current Ratio
- 1.48
- 3.30
- Quick Ratio
- 1.30
- 2.42
- Debt / Equity
- 0.79
- 0.49
- Interest Coverage
- -0.55
- -6.35
GrowthIndustry
- Revenue Growth (YoY)
- 17.0%
- 7.01%
- Revenue Growth (3Y CAGR)
- -5.66%
- 2.25%
- Revenue Growth (5Y CAGR)
- 6.79%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.74
- 0.40
- Inventory Turnover
- 2.42
- 2.73
- Revenue Per Employee
- $1.20M
- $429.29K
- Profits Per Employee
- -$88.00K
- -$683.67K
- Employee Count
- 58
- 75
- WACC
- 8.87%
- 10.1%
Income statement (TTM)Industry
- Pretax Income
- -$5.09M
- -$13.23M
Balance sheetIndustry
- Net Cash (Debt)
- -$3.25M
- $17.46M
- Net Cash Per Share
- -$0.12
- $0.72
- Equity (Book Value)
- $32.25M
- $53.27M
- Book Value Per Share
- $1.14
- $1.50
- Tangible Book Value
- $7.71M
- $26.82M
- Working Capital
- $25.74M
- $79.47M
Cash flow (TTM)Industry
Dividends and yieldsIndustry
- Earnings Yield
- -4.12%
- -20.8%
Taxes and interestIndustry
- Interest Expense
- $3.65M
- $2.93M
Scores and fair valueIndustry
- Altman Z-Score
- 0.56
- 0.30
- Piotroski F-Score
- 5
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | DERM | S&P 500 | Difference | DERM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.7% | -2.7% | −23.0 pts | ||
| 3 months | -31.7% | -1.7% | −30.0 pts | ||
| Year to date | -43.1% | +11.9% | −55.0 pts | ||
| 1 year | -51.7% | +12.0% | −63.6 pts | ||
| 3 years | +17.7% | +78.2% | −60.5 pts | +5.6% | +21.2% |
| 5 years | -53.8% | +73.2% | −127.0 pts | -14.3% | +11.6% |
| 10 years | -87.5% | +309.6% | −397.2 pts | -18.8% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
3M DERM shares were sold short on Oct 30, 2026, up 3.2% from the previous report, or 12.91% of the shares available to trade. At recent volumes it would take 15.1 days to buy them back. Over the last 20 sessions, 45.3% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 3,085,027 | +3.2% | 204,724 | 15.1 |
| Oct 15, 2026 | 2,987,988 | -2.2% | 180,196 | 16.6 |
| Sep 30, 2026 | 3,055,846 | +4.4% | 219,731 | 13.9 |
| Sep 15, 2026 | 2,927,514 | -1.1% | 130,023 | 22.5 |
| Aug 31, 2026 | 2,961,399 | +1.5% | 169,699 | 17.4 |
| Aug 14, 2026 | 2,917,410 | +1.5% | 280,041 | 10.4 |
| Jul 31, 2026 | 2,874,752 | -5.8% | 140,066 | 20.5 |
| Jul 15, 2026 | 3,052,065 | +2.1% | 160,958 | 19.0 |
| Jun 30, 2026 | 2,990,671 | -14.9% | 566,775 | 5.3 |
| Jun 15, 2026 | 3,515,425 | +0.0% | 167,828 | 20.9 |
| May 29, 2026 | 3,514,547 | +1.4% | 247,363 | 14.2 |
| May 15, 2026 | 3,467,690 | -5.6% | 304,396 | 11.4 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?